<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04069884</url>
  </required_header>
  <id_info>
    <org_study_id>RIGAIN</org_study_id>
    <nct_id>NCT04069884</nct_id>
  </id_info>
  <brief_title>RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer</brief_title>
  <acronym>RIGAIN</acronym>
  <official_title>RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiaobo Huang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was divided into two randomized controlled trials. The purpose of this study is to
      validate whether clinically high-risk, and RecurIndex low-risk N1 patients omitting regional
      lymph node radiotherapy can do well with good prognosis, or whether clinically low-risk, and
      RecurIndex high-risk N1 patients receiving regional lymph node radiotherapy can further
      improve clinical outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2029</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Invasive disease-free survival (IDFS)</measure>
    <time_frame>5 years</time_frame>
    <description>defined as the time between randomization and either local recur, distant metastases or death occurred</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any first recurrence (AFR)</measure>
    <time_frame>5 years</time_frame>
    <description>defined as any recurrence of ipsilateral chest, breast, regional lymph node recurrence, or distant metastases by Imaging or pathology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local-regional recurrence free survival (LRFS)</measure>
    <time_frame>5 years</time_frame>
    <description>defined as time between randomization and the time of any recurrence of ipsilateral chest, breast, regional lymph node recurrence, distant metastases, or death occurred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis free survival (DMFS)</measure>
    <time_frame>5 years</time_frame>
    <description>defined as time between randomization and the time of distant metastases, or death occurred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival (RFS)</measure>
    <time_frame>5 years</time_frame>
    <description>defined as time between randomization and the time of any recurrence of ipsilateral chest, breast, regional lymph node recurrence, distant metastases, or death occurred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>defined as time between randomization and the time of death occurred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>5 years</time_frame>
    <description>defined as time between randomization and the time of disease recur or death occur</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beast cancer specific mortality (BCSM)</measure>
    <time_frame>5 years</time_frame>
    <description>defined as time between randomization and the time of death occur specific due to breast cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient life quality measurement</measure>
    <time_frame>5 years</time_frame>
    <description>At the screening period and after the end of radiotherapy, each group of patients was enrolled in the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Cancer-30 (C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient life quality measurement</measure>
    <time_frame>5 years</time_frame>
    <description>At the screening period and after the end of radiotherapy, each group of patients was enrolled in the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Breast-23 (BR23)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1834</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Radiation</condition>
  <arm_group>
    <arm_group_label>Arm I (Clinical high-risk, RecurIndex low-risk)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regional nodal irradiation (RNI) was given along with whole breast irradiation (WBI) or Chest wall irradiation (CWI) for breast-conserving patients and total mastectomy patients, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (Clinical high-risk, RecurIndex low-risk)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No Regional nodal irradiation (RNI) , whole breast irradiation (WBI) for breast-conserving patients and No Chest wall irradiation (CWI) for total mastectomy patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (Clinical low-risk, RecurIndex high-risk)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No Regional nodal irradiation (RNI) , whole breast irradiation (WBI) for breast-conserving patients and No Chest wall irradiation (CWI) for total mastectomy patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (Clinical low-risk, RecurIndex high-risk)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regional nodal irradiation (RNI) was given along with whole breast irradiation (WBI) or Chest wall irradiation (CWI) for breast-conserving patients and total mastectomy patients, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>regional nodal irradiation</intervention_name>
    <description>external-beam radiotherapy (XRT)</description>
    <arm_group_label>Arm I (Clinical high-risk, RecurIndex low-risk)</arm_group_label>
    <arm_group_label>Arm IV (Clinical low-risk, RecurIndex high-risk)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>WBI</intervention_name>
    <description>Whole Breast Irradiation</description>
    <arm_group_label>Arm I (Clinical high-risk, RecurIndex low-risk)</arm_group_label>
    <arm_group_label>Arm II (Clinical high-risk, RecurIndex low-risk)</arm_group_label>
    <arm_group_label>Arm III (Clinical low-risk, RecurIndex high-risk)</arm_group_label>
    <arm_group_label>Arm IV (Clinical low-risk, RecurIndex high-risk)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>chestwall XRT</intervention_name>
    <description>chestwall irradiation</description>
    <arm_group_label>Arm I (Clinical high-risk, RecurIndex low-risk)</arm_group_label>
    <arm_group_label>Arm IV (Clinical low-risk, RecurIndex high-risk)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old, ≤ 70 years old.

          -  Eastern Cooperative Oncology Group (ECOG) ≤ 2.

          -  Postoperative pathology is clearly diagnosed as invasive breast cancer.

          -  Postoperative pathological diagnosis of axillary lymph node status is any of the
             following: a. Sentinel lymph node biopsy or axillary lymph node dissection for
             micrometastasis (N1mic), b. Sentinel lymph node biopsy for 1-2 lymph node
             macrometastasis (N1sln), c. Sentinel lymph node biopsy + axillary lymph node
             dissection or simple axillary lymph node dissection for 1-3 lymph node metastasis
             (N1).

          -  The primary tumor and breast undergo breast-conserving surgery or total resection ±
             breast reconstruction (autologous/prosthetic).

          -  There must be adequate systemic examination (such as chest X-ray, B-ultrasound, CT,
             etc.) within 3 months before randomization of radiotherapy to confirm that there is no
             distant metastasis.

          -  Preoperative or radiotherapy should be performed within 12 months of randomization and
             must have mammography and/or MRI to confirm that there is no contralateral breast
             cancer.

          -  At least 4 courses of adjuvant chemotherapy with anthracycline or taxane should be
             completed after surgery.

          -  Radiotherapy must be performed sequentially after the completion of adjuvant
             chemotherapy, starting no later than 8 weeks after the end of chemotherapy.

          -  The patient must have sufficient primary fresh frozen specimens or post-paraffin
             tissue sections for RecurIndex testing.

          -  No previous history of malignant tumors, except for basal cell carcinoma of the skin.

          -  Signed an informed consent form.

        Exclusion Criteria:

          -  Postoperative radiotherapy was confirmed as T3-4, N0, N2-3, M1 lesion staging before
             enrollment.

          -  Receive any new adjuvant therapy before surgery, including chemotherapy, endocrine
             therapy, targeted therapy or radiation therapy.

          -  Patients who underwent total mastectomy and only sentinel lymph node biopsy.

          -  Have a history of contralateral breast cancer.

          -  History of chest radiotherapy.

          -  combined with severe heart, lung, liver, kidney, hematopoietic, neurological diseases,
             and mental illness.

          -  History of autoimmune diseases such as scleroderma or active lupus erythematosus.

          -  pregnant and lactating patients.

          -  Unable or unwilling to sign an informed consent form.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaobo Huang, MD</last_name>
    <phone>8613556080080</phone>
    <email>huangxb@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tan Yuting</last_name>
    <phone>8615913198466</phone>
    <email>tanyt3@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaobo Y Huang, MD</last_name>
      <phone>8613556080080</phone>
      <phone_ext>8613556080080</phone_ext>
      <email>huangxb@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yuting Y Tan</last_name>
      <phone>8615913198466</phone>
      <phone_ext>8613556080080</phone_ext>
      <email>tanyt3@mail.sysu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaobo Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuting Tan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fengxi Su, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Huang TT, Chen AC, Lu TP, Lei L, Cheng SH. Clinical-Genomic Models of Node-Positive Breast Cancer: Training, Testing, and Validation. Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):637-648. doi: 10.1016/j.ijrobp.2019.06.2546. Epub 2019 Jul 8.</citation>
    <PMID>31295565</PMID>
  </reference>
  <results_reference>
    <citation>Cheng SH, Horng CF, West M, Huang E, Pittman J, Tsou MH, Dressman H, Chen CM, Tsai SY, Jian JJ, Liu MC, Nevins JR, Huang AT. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol. 2006 Oct 1;24(28):4594-602.</citation>
    <PMID>17008701</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheng SH, Horng CF, Huang TT, Huang ES, Tsou MH, Shi LS, Yu BL, Chen CM, Huang AT. An Eighteen-Gene Classifier Predicts Locoregional Recurrence in Post-Mastectomy Breast Cancer Patients. EBioMedicine. 2016 Feb 16;5:74-81. doi: 10.1016/j.ebiom.2016.02.022. eCollection 2016 Mar.</citation>
    <PMID>27077114</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheng SH, Horng CF, Clarke JL, Tsou MH, Tsai SY, Chen CM, Jian JJ, Liu MC, West M, Huang AT, Prosnitz LR. Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1401-9. Epub 2006 Feb 10.</citation>
    <PMID>16472935</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheng SH, Tsai SY, Yu BL, Horng CF, Chen CM, Jian JJ, Chu NM, Tsou MH, Liu MC, Huang AT, Prosnitz LR. Validating a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer. Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):953-8. doi: 10.1016/j.ijrobp.2012.08.042. Epub 2012 Nov 1.</citation>
    <PMID>23122982</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheng SH, Huang TT, Cheng YH, Tan TBK, Horng CF, Wang YA, Brian NS, Shih LS, Yu BL. Validation of the 18-gene classifier as a prognostic biomarker of distant metastasis in breast cancer. PLoS One. 2017 Sep 8;12(9):e0184372. doi: 10.1371/journal.pone.0184372. eCollection 2017.</citation>
    <PMID>28886126</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang TT, Pennarun N, Cheng YH, Horng CF, Lei J, Hung-Chun Cheng S. Gene expression profiling in prognosis of distant recurrence in HR-positive and HER2-negative breast cancer patients. Oncotarget. 2018 May 1;9(33):23173-23182. doi: 10.18632/oncotarget.25258. eCollection 2018 May 1.</citation>
    <PMID>29796180</PMID>
  </results_reference>
  <results_reference>
    <citation>Pittman J, Huang E, Dressman H, Horng CF, Cheng SH, Tsou MH, Chen CM, Bild A, Iversen ES, Huang AT, Nevins JR, West M. Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8431-6. Epub 2004 May 19.</citation>
    <PMID>15152076</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, West M, Nevins JR, Huang AT. Gene expression predictors of breast cancer outcomes. Lancet. 2003 May 10;361(9369):1590-6.</citation>
    <PMID>12747878</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 24, 2019</last_update_submitted>
  <last_update_submitted_qc>August 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Fengxi Su</investigator_full_name>
    <investigator_title>Head of Breast Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>individual patient data (IPD) will be shared when the research is published.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>The data will become available in 2030 and forever.</ipd_time_frame>
    <ipd_access_criteria>Study Protocol</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

